

Supplemental Material

Table S1. CVD Mortality among participants free of CVD According to Sex-Specific Quartiles.

FABP-4 Range	Person-Time	Deaths	Rate	95% CI
Men				
≤18.64	5329.6	117	21.9	18.3-26.3
18.65-23.63	4894.6	129	26.4	22.2-31.3
23.64-30.58	4554.7	131	28.8	24.2-34.1
>30.58	3421.2	115	33.6	28.0-40.3
Women				
≤27.56	8531.6	162	19.0	16.3-22.1
27.57-35.25	8917.3	173	19.4	16.7-22.5
35.26-45.91	8665.7	197	22.7	19.8-26.1
>45.91	7531.4	189	25.1	21.8-28.9

FABP-4: Fatty acid binding protein

Table S2. Hazard ratios (95% confidence intervals) of cardiovascular mortality associated with circulating levels of FABP-4 among participants free of CVD in sex-specific quartiles.

	Q1	Q2	Q3	Q4	per doubling
Cardiovascular Mortality⁺					
WOMEN					
	≤27.56	>27.56-35.25	>35.25-45.91	>45.91	
Model 1 [#]	(Ref.)	0.99 (0.79-1.23)	1.16 (0.93-1.44)	1.25 (0.99-1.58)	1.23 (1.07-1.42)
Model 2 [*]	(Ref.)	0.94 (0.75-1.17)	1.16 (0.93-1.44)	1.09 (0.86-1.38)	1.14 (0.99-1.32)
Model 3 ⁺	(Ref.)	0.95 (0.76-1.18)	1.16 (0.93-1.44)	1.10 (0.87-1.39)	1.14 (0.99-1.32)
MEN					
	≤18.65	>18.64-23.63	>23.63-30.58	>30.58	
Model 1 [#]	(Ref.)	1.20 (0.92-1.55)	1.33 (1.02-1.73)	1.64 (1.23-2.21)	1.54 (1.27-1.87)
Model 2 [*]	(Ref.)	1.13 (0.87-1.46)	1.22 (0.93-1.60)	1.49 (1.10-2.00)	1.41 (1.16-1.71)
Model 3 ⁺	(Ref.)	1.08 (0.83-1.40)	1.17 (0.89-1.53)	1.35 (1.00-1.83)	1.33 (1.09-1.63)

[#] Adjusted for age, sex, race, field center, waist circumference

^{*} Adjusted for age, sex, race, field center, waist circumference, systolic BP, anti-hypertensive medications, HDL, LDL, triglycerides, CRP, fasting glucose, hypoglycemic medications

⁺ Adjusted for age, sex, race, field center, waist circumference, systolic BP, anti-hypertensive medications, HDL, LDL, triglycerides, CRP, fasting glucose, hypoglycemic medications, diastolic BP, grip strength, physical activity, heart rate

P-values for interaction per doubling:

Model 1: p=0.18

Model 2: p=0.03

Model 3: p=0.07

Table S3. CVD Mortality among participants with prevalent CVD according to Sex-Specific Quartiles.

FABP-4 Range	Person-Time	Deaths	Rate	95% CI
Men				
≤18.64	838.0	33	39.4	28.0-55.4
18.65-23.63	775.7	49	63.2	47.7-83.6
23.64-30.58	761.6	48	63.0	47.5-83.6
>30.58	884.6	72	81.4	64.6-102.5
Women				
≤27.56	570.7	17	29.8	18.5-47.9
27.57-35.25	760.2	30	39.4	27.6-56.4
35.26-45.91	618.2	28	45.3	31.3-65.6
>45.91	767.0	54	70.4	53.9-91.9

FABP-4: Fatty acid binding protein

Table S4. Hazard ratios (95% confidence intervals) of cardiovascular mortality associated with circulating levels of FABP-4 among participants with prevalent CVD according to sex-specific quartiles.

	Q1	Q2	Q3	Q4	per doubling
Cardiovascular Mortality⁺					
WOMEN					
	≤27.56	>27.56-35.25	>35.25-45.91	>45.91	
Model 1 [#]	(Ref.)	1.44 (0.79-2.65)	1.75 (0.93-3.31)	2.65 (1.47-4.79)	1.74 (1.26-2.40)
Model 2 [*]	(Ref.)	1.52 (0.80-2.87)	1.68 (0.84-3.36)	2.44 (1.27-4.67)	1.62 (1.12-2.33)
Model 3 ⁺	(Ref.)	1.64 (0.86-3.13)	1.78 (0.89-3.58)	2.60 (1.35-4.99)	1.65 (1.14-2.38)
MEN					
	≤18.65	>18.64-23.63	>23.63-30.58	>30.58	
Model 1 [#]	(Ref.)	1.90 (1.19-3.04)	2.02 (1.23-3.32)	2.82 (1.74-4.55)	1.86 (1.43-2.43)
Model 2 [*]	(Ref.)	1.91 (1.18-3.08)	1.91 (1.15-3.16)	2.52 (1.51-4.19)	1.69 (1.27-2.24)
Model 3 ⁺	(Ref.)	1.84 (1.12-3.00)	1.84 (1.10-3.09)	2.37 (1.40-4.00)	1.61 (1.19-2.16)

[#] Adjusted for age, sex, race, field center, waist circumference

^{*} Adjusted for age, sex, race, field center, waist circumference, systolic BP, anti-hypertensive medications, HDL, LDL, triglycerides, CRP, fasting glucose, hypoglycemic medications

⁺ Adjusted for age, sex, race, field center, waist circumference, systolic BP, anti-hypertensive medications, HDL, LDL, triglycerides, CRP, fasting glucose, hypoglycemic medications, diastolic BP, grip strength, physical activity, heart rate
P-values for interaction per doubling:

Model 1: p=0.96

Model 2: p=1.0

Model 3: p=0.83